There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK – Research Report), AbbVie (ABBV – Research Report) and Establishment Labs Holdings (ESTA – Research Report) with bullish sentiments.
Cytokinetics (CYTK)
In a report released today, Tessa Romero from J.P. Morgan maintained a Buy rating on Cytokinetics. The company’s shares closed last Monday at $57.89.
According to TipRanks.com, Romero is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $96.15 average price target, implying a 51.8% upside from current levels. In a report issued on May 8, Goldman Sachs also maintained a Buy rating on the stock with a $85.00 price target.
See the top stocks recommended by analysts >>
AbbVie (ABBV)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on AbbVie today and set a price target of $200.00. The company’s shares closed last Monday at $161.28.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Currently, the analyst consensus on AbbVie is a Strong Buy with an average price target of $185.27, a 14.9% upside from current levels. In a report issued on April 29, Truist Financial also maintained a Buy rating on the stock.
Establishment Labs Holdings (ESTA)
In a report issued on May 8, Josh Jennings from TD Cowen maintained a Buy rating on Establishment Labs Holdings, with a price target of $60.00. The company’s shares closed last Monday at $56.19.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Currently, the analyst consensus on Establishment Labs Holdings is a Strong Buy with an average price target of $60.00, implying a 6.5% upside from current levels. In a report issued on May 2, Mizuho Securities also reiterated a Buy rating on the stock with a $65.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYTK:
- Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
- Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
- Cytokinetics price target lowered to $106 from $107 at Oppenheimer
- Cytokinetics price target lowered to $106 from $110 at JMP Securities
- Cytokinetics Reports First Quarter 2024 Financial Results
